Trodelvy-Immunotherapy Combinations In Solid Tumors: Rationale & Emerging Data
Time: 9:15 am
day: Day Two AM
Details:
- Recapping and contextualizing recent data from Phase II EVOKE-02 trial of Troveldy-Keytruda combinations in lung cancer
- Evaluating rationale and design of Trodelvy-immunotherapy combinations in other solid tumors
- Breaking down the potential – what are the route forward and potential of novel ADC-immunotherapy combinations?
